Mild cognitive impairment due to Alzheimer's disease
Conditions
Interventions
Experimental Group:Treatment of underlying diseases with western medicine + Polygonum cuspidatum Yizhi granules
Control group:Treatment of underlying diseases with western medicine + Polygonum cuspidatum Yizhi placebo granules
Sponsors
Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1 Age =18 years and =85 years; No gender limit. 2 Met the diagnostic criteria for MCI-AD. 3 Positive PET-CT or plasma Aß. 4 MoCA < 26. 5 Understand and agree to participate in this study and sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1 Intracranial and extracranial vascular examination confirmed that the degree of vascular stenosis was =50%. 2. Imaging data showed the presence of intracranial space-occupying lesions. Other neurological or psychiatric disorders with a definite etiology previously diagnosed: It mainly includes stroke (except lacunar infarction), neurodegenerative diseases (Parkinson's disease, dementia with Lewy bodies, etc.), dementia caused by other causes (including autoimmune, metabolic, toxicity-related intracranial lesions, etc.), hydrocephalus, and psychiatric disorders diagnosed according to DSM-V diagnostic criteria. 4 Previously diagnosed cardiovascular events (including myocardial infarction, angina pectoris, prior internal carotid endarterectomy or stenting, coronary stenting, or coronary artery bypass surgery). "5 The patient also has other serious illnesses (e.g., cancer, heart failure, respiratory failure, renal failure and severe liver damage, severe hematologic disease or gastrointestinal bleeding)." 6. Severe impairment of vision, hearing, or language function, or poor limb muscle strength, unable to cooperate with the relevant examination. 7 had clear contraindications or adverse effects to the drug components. 8 People who were taking drugs or other traditional Chinese medicine compound drugs to improve or affect cognitive function within 1 month or currently. 9 Being in clinical trials of other drugs within 1 month or currently. Surgery is planned within 1 year. 11 Pregnant or lactating women. 12 The collection of clinical data conforming to the analysis of this study could not be completed for various other reasons.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ADAS-cog scale score;Neuropsychological scales;Degree of GAIT Improvement; | — |
Secondary
| Measure | Time frame |
|---|---|
| 7.0T magnetic resonance imaging; | — |
Countries
China
Contacts
Public ContactYan Han
Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine
Outcome results
None listed